TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00847444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug-based intervention
Description: Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle-based Intervention
Description: All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention.
Study: NCT02214121

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor Dose 1a + Dose 2a
Description: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor Dose 1b + Dose 2b
Description: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
Study: NCT02403908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nMARQ Circular and Crescent catheters
Description: Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
Study: NCT02187328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Description: Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple juice
Description: Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
Study: NCT01779193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactic acid bacteria
Description: oral lactobacillus capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cranberry
Description: oral cranberry capsule, one pill daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cranberry
Description: oral cranberry capsule, one pill daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule without lactic acid bacteria and cranberry, one pill daily
Study: NCT04090554

Intervention type: DEVICE
Group type: OTHER
Intervention: Cytosponge™
Description: The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
Study: NCT00545714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
Study: NCT03869944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Oral Solution
Description: During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART.
Study: NCT04154631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Delayed Treatment
Description: Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
Study: NCT04262648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri
Description: Lactobacillus Reuteri NCIMB 30351

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sunflower oil
Study: NCT02749500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy (OT)
Description: Standard of care occupational therapy for stroke recovery
Study: NCT04409262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV placebo matched to TCZ
Study: NCT02749500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Occupational Therapy (OT)
Description: Standard of care occupational therapy for stroke recovery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m2 BAT
Description: Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
Study: NCT00401661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: One tablet of 10mg once daily at the end of evening meal
Study: NCT02087657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Administration of hyperbaric oxygen
Description: Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
Study: NCT02287714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Instep without gastrocnemius recession
Description: Patient will receive an instep plantar fascial release without gastrocnemius recession.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instep with gastrocnemius recession
Description: Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
Study: NCT01546428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Study: NCT02712723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Nonsteroidal aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Nonsteroidal aromatase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Nonsteroidal aromatase inhibitor
Study: NCT01597713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
Study: NCT02712723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Oral cyclin-dependent kinase (CDK) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Oral cyclin-dependent kinase (CDK) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for ribociclib
Study: NCT01597713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of oral placebo within each dose group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
Study: NCT01385774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty
Description: The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Therapy
Description: Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
Study: NCT00054405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV
Study: NCT01597713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0148-0000-0362
Description: Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
Study: NCT02219412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: 90 mg bid for 2 weeks
Study: NCT04047979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix®
Description: A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix®
Description: A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
Study: NCT02251938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-109 440 μg
Description: Medium Dose
Study: NCT02428569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARED Decision Support
Description: The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
Study: NCT03190889

Intervention type: OTHER
Group type: OTHER
Intervention: HOME
Description: At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TNMT
Description: Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
Study: NCT04766775

Intervention type: DEVICE
Group type: OTHER
Intervention: Silver Diamine Fluoride
Description: Silver Diamine Fluoride (Riva Star) which contains silver, fluoride, ammonia and water.
Study: NCT02110862

Intervention type: OTHER
Intervention: Transittime. Defecography
Study: NCT02473367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg
Description: Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUMS
Description: Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
Study: NCT02219412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: 90 mg bid for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg Qd for 2 weeks.
Study: NCT04331613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAStem
Description: CAStem will be administered intravenously.
Study: NCT02386293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill made to look identical to irbesartan intervention.
Study: NCT02473367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leader Antacid
Description: 20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
Study: NCT02225834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
Study: NCT03525886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-74788
Description: Capsule, administered daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-74788
Description: Capsule, administered daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-74788
Description: Capsule, administered daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-74788
Description: Capsule, administered daily.
Study: NCT04530643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209 0.3%
Description: 25 subjects will be assigned to drug (HY209 0.3% gel).
Study: NCT03190460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Technology-based Education
Description: Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
Study: NCT01389037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy-focused Self-help
Description: Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Intervention Control
Description: Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
Study: NCT04530643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209 0.5%
Description: 25 subjects will be assigned to drug (HY209 0.5% gel).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 subjects will be assigned to drug (Placebo).
Study: NCT03950154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection [Avastin]
Description: Bevacizumab injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection [Avastin]
Description: Bevacizumab injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine oral agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine oral agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1-T cells
Description: PD1-T cells injection
Study: NCT03565146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4 Laser System
Description: PiQo4 Laser System for treatment of pigmented lesions
Study: NCT01927900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO
Study: NCT00650975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Thromboablation
Description: Laser Thromboablation using the Spectranetics CVX-300® excimer laser system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA (Direct Stenting)
Description: Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
Study: NCT00988910

Intervention type: DRUG
Intervention: EE30-DRSP (Yasmin, BAY86-5131)
Description: DRSP-containing combined oral contraceptives according to the normal routine praxis

Intervention type: DRUG
Intervention: Other combined oral contraceptives
Description: Other combined oral contraceptives according to the normal routine praxis
Study: NCT03870399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: The treatment to be used will be tamoxifen 20mg orally once daily.
Study: NCT04248023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: A practice facilitator will be assigned the each participating practice to assist with the development of a workflow, screening process, counseling resources, and referral resources for unhealthy alcohol use. Practices in control group will receive delayed intervention at 3 months after their matched cohort of practices.
Study: NCT00269854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 20 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
Study: NCT01927900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Study: NCT00269854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be adminstered at Week 0, 2 and 6.
Study: NCT02274740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIXISENATIDE AVE0010
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00656435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
Study: NCT04007419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Promoters and Organ Donation
Description: Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.